PREVAILING PERCEPTION OF NEWER ORAL ANTICOAGULANT: RIVAROXABAN
Asiya Parveen, Shazia Parveen, Nadeem Siddiqui*, M. Shahar Yar, Vivek Kumar and Sharique Ahmed
ABSTRACT
Newer oral anticoagulants (NOACs) possess enhanced activity in control of cardiovascular disease. Rivaroxaban, a factor Xa inhibitor approved by FDA in 2011 is effective in nonvalvular atrial fibrillation (NVAF). The drug also possess significant pharmacokinetics features. The oral route of administration, consistent dose, improved specificity without requiring periodic checkups, patient monitoring and having more benefits. With little chance of interfering with food or other medications, rivaroxaban exhibits a quick onset of anticoagulant effect. There's no need for frequent monitoring and it can be administered at set dosages. This article provides an overview of the drug profile, synthesis, mechanism, admission route, pharmacokinetics, and medical indication of rivaroxaban, describing the pharmacodynamic profile and computational study. This study gives current insight to rivaroxaban being a safe option for physicians with advanced therapeutic choice.
Keywords: Rivaroxaban; Atrial fibrillation; Factor Xa; Synthesis; Mechanism; Molecular docking; Spectral prediction.
[Full Text Article]
[Download Certificate]